Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Topical Corticosteroid Rx-To-OTC Switch Safety To Be Considered By NDAC

This article was originally published in The Tan Sheet

Executive Summary

The Nonprescription Drugs and Dermatologic & Ophthalmic Drugs (DODAC) advisory committees will discuss guidelines on adequate safety information when considering Rx-to-OTC switches of topical corticosteroids during a March 24 meeting

You may also be interested in...

Antiseptic meeting

Anti-infective Drugs Advisory Committee meeting scheduled for May 11 has been cancelled, according to committee hotline. Panelists were to discuss microbiologic endpoints as substitutes for effectiveness in clinical trials intended to address the safety and efficacy of antiseptic health care drug products (1"The Tan Sheet" March 22, 2004, In Brief). FDA has not announced a new date for the meeting...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts